Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
equine influenza vaccine (TVG)
- Development stage
- Preclinical
- Lead developer
- TVG
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
A herpesvirus-based viral-vector vaccine being developed by The Vaccine Group (TVG) for the prevention of equine influenza. The vaccine platform utilizes a modified herpesvirus to deliver equine influenza virus antigens, aiming to stimulate a protective immune response in horses. The program is currently in the preclinical stage of development.
- Other names
- equine influenza virus vaccineherpesvirus-based viral-vector equine influenza vaccine
02
Targets
EIV antigen (Equine influenza virus antigen)
Beyond the preview
Go deeper on equine influenza vaccine (TVG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on equine influenza vaccine (TVG).